Veterinary Stability Data: What VICH GL3 Covers and What It Leaves Out

Stability data underpin the shelf life and storage statements on every veterinary medicine, and VICH GL3 is the harmonised starting point, but it is written for new molecular entities and does not answer every question a real dossier raises.

The scope of VICH GL3

VICH GL3 sets out stability testing expectations for registration applications for new veterinary drug substances and the medicinal products made from them. According to EMA, it does not extend to abbreviated or abridged applications, variations or clinical trial applications. The current text is Revision 1, with a legal effective date of 1 January 2008. Companion VICH guidelines address specific situations, so the first step is always to confirm which guideline governs your product type.

What the Quality part has to show

  • A stability protocol that is justified for the product, packaging and intended markets.
  • Data from batches representative of the commercial process, generated with validated stability-indicating methods.
  • Evidence supporting the proposed shelf life and the storage conditions printed on the label and package leaflet.
  • For products that are reconstituted, diluted or opened in use, in-use stability data that reflect how the product is actually handled on farms and in clinics.

Veterinary-specific considerations

Veterinary products often differ from human ones in ways that matter for stability design: multi-dose vials broached many times, medicated premixes added to feed, products given in drinking water, and large-volume containers used over days. Each creates an in-use question that the standard long-term and accelerated programme does not answer. Regulators expect the programme to follow the real use pattern, not simply the guideline template.

Where dossiers go wrong

  • Applying the guideline to a generic or variation where a different approach is expected.
  • Relying on development batches that do not represent commercial scale.
  • Leaving in-use and post-dilution claims unsupported.
  • Proposing a shelf life without a clear commitment to continue studies on commercial batches.

Keeping the data alive after approval

Stability does not end at authorisation. Ongoing studies, changes of packaging, site or process, and any extension of shelf life all feed back into the variations framework. Treating the stability programme as part of lifecycle management avoids surprises at the next change.

Related reading

How PQRA helps

PQRA reviews veterinary Quality sections for completeness and consistency, helps design stability protocols that match real use, and supports the variations that follow when shelf life, packaging or manufacturing sites change.

Ready to talk it through? Contact the PQRA team.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *